Table 2 Antibiotic use within six months prior to detection of VREfm in the study population
|  | All patients (n = 33) | VREfm-colonised patients (n = 26) | VREfm-colonised patients with suspected infection (n = 7) | p value* |
|---|---|---|---|---|
Antibiotics total, median (range) | 5 (0–14) | 5 (0–14) | 7 (3–14) | 0.150 |
Antibiotic classes, n (%) | Â | Â | Â | Â |
Aminoglycosides | 5 (15.2) | 5 (19.2) | 0 (0.0) | 0.559 |
Beta-lactam/beta-lactamase inhibitor | 22 (66.7) | 16 (61.5) | 6 (85.7) | 0.378 |
Carbapenems | 16 (48.5) | 10 (38.5) | 6 (85.7) | 0.039 |
First-generation cephalosporins | 3 (9.1) | 3 (11.5) | 0 (0.0) | 1.000 |
Fluoroquinolones | 1 (3.0) | 0 (0.0) | 1 (14.3) | 0.212 |
Glycopeptides | 11 (33.3) | 9 (34.6) | 2 (28.6) | 1.000 |
Imidazoles | 4 (12.1) | 3 (11.5) | 1 (14.3) | 1.000 |
Macrolides | 6 (18.2) | 6 (23.1) | 0 (0.0) | 0.301 |
Penicillins | 12 (36.4) | 11 (42.3) | 1 (14.3) | 0.223 |
Phosphonics | 1 (3.0) | 0 (0.0) | 1 (14.3) | 0.212 |
Second-generation cephalosporins | 8 (24.2) | 7 (26.9) | 1 (14.3) | 0.652 |
Third-generation cephalosporins | 14 (42.4) | 13 (50.0) | 1 (14.3) | 0.195 |
Trimethoprim/sulfonamide combinations | 9 (27.3) | 5 (19.2) | 4 (57.1) | 0.068 |
Unknown antibiotic class | 2 (6.1) | 2 (7.7) | 0 (0.0) | 1.000 |
Antibiotic groups AWaRe classification†|  |  |  |  |
Access Antibiotics, median (range) | 1 (0–6) | 1 (0–6) | 1 (0–3) | 0.629 |
Watch Antibiotics, median (range) | 4 (0–13) | 3 (0–13) | 4 (2–12) | 0.120 |